Shares of Ocugen Inc. OCGN rallied 4.94% to $0.58 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.22% to 5,662.89 and Dow ...

After review by the Data and Safety Monitoring Board, the dosing of OCU200 in patients with diabetic macular edema (DME) will continue.

Ocugen Inc. closed 73.92% short of its 52-week high of $2.11, which the company reached on March 25th.

Ocugen has received approval from the DSMB to begin dosing the second cohort of patients in a trial of OCU200 for diabetic ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic ...

Ocugen (OCGN) announced that the Data and Safety Monitoring Board for the OCU200 clinical trial recently convened and reviewed safety data ...

Armed with new data from its development partner Bharat Biotech, Ocugen is planning to press ahead with plans to file for approval of their COVID-19 vaccine Covaxin in the US and Canada.

Throughout the last three months, 5 analysts have evaluated Ocugen (NASDAQ:OCGN), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their ...

Full Year 2024 Results Key Financial Results Net loss: US$54.1m (loss narrowed by 14% from ...

Ocugen Inc (OCGN) outlines pivotal trial progress and financial strategies while navigating increased expenses and market competition.

Tiffany Hamilton; Head of Communications; Ocugen Inc. Shankar Musunuri; Chairman of the Board, Chief Executive Officer & Co-founder; Ocugen Inc. Ramesh Ramachandran; ...